Your Pharmacy Benefit Is Hiding Something
Specialty drugs are 2% of prescriptions. They're eating 52% of net drug spend, according to Navitus Health Solutions. That's over $400 billion in 2025 alone.
This is the carve-out vs. carve-in decision. Most mid-market employers never make it consciously. They just inherit whatever the carrier bundled together at renewal.
That default choice has a price tag. For a 250-life employer, the difference can run $400 per member per year in downstream medical costs. Here's what each side actually gives you.
What Carve-In Gets You (and What It Costs)
A carve-in means your pharmacy benefit lives inside your medical contract. The carrier manages both. It feels simple. One vendor, one invoice, less friction at the administrator level.
The clinical integration argument is real. A peer-reviewed study published in PMC found that carve-in designs were associated with a 17.7% reduction in hospitalizations and a 3.7% reduction in total medical costs versus carve-out designs.
A separate analysis citing Smith et al. corroborated a 15% hospitalization reduction. Highmark, HealthPartners, Aetna, and Cigna all backed similar findings.
At mid-market PMPY rates, that 3.7% medical cost reduction translates to roughly $400 PMPY in avoided downstream spend. That's not nothing. Over a 2-3 year horizon, it compounds.
But here's what carve-in doesn't give you. Direct visibility into your contract. Guaranteed rebate pass-through at the client level.
No audit rights. None of it. Per RxBenefits, those features are typically absent in a carve-in model. You're trusting the carrier to manage both cost centers in your interest. That's a significant assumption.
What Carve-Out Actually Gives You
A pharmacy carve-out means you contract directly with a PBM vendor, separate from your medical carrier. You get your own contract terms. You negotiate your own discounts.
RxBenefits identifies the specific advantages: guaranteed discounts and rebates at the client level, auditing rights, and direct visibility into your pharmacy contract. You also get tailored clinical management and proactive utilization oversight.
That's real pricing control, not a summary report at renewal.
Why does this matter? According to Navitus, costs on specialty medications can vary by tens of thousands of dollars depending on the PBM involved. Without a direct contract and audit rights, you can't catch the spread. You can't negotiate it away. You just pay it. And the spread isn't always visible at the PBM level, either. Affiliated GPOs can strip rebate dollars out before they ever hit your pass-through calculation.
The Medicaid data adds useful texture. The Menges Group found that carve-in states ran $38.47 PMPM in net post-rebate pharmacy costs vs. $34.58 PMPM for carve-out states. That's a $3.89 PMPM disadvantage for carve-in, before medical offset savings are factored in. Even in a public program with significant negotiating scale, the pricing gap was real.
What a 250-Life Employer Is Actually Deciding
Run the math on both sides. Carve-out gives you pricing transparency, audit rights, and direct contract control today. Carve-in gives you integrated data and a documented reduction in hospitalizations and total medical spend over time.
| Factor | Carve-Out | Carve-In |
|---|---|---|
| Contract transparency | Direct, auditable | Limited, carrier-controlled |
| Rebate pass-through | Guaranteed at client level | Pooled or opaque |
| Audit rights | Yes | Typically absent |
| Clinical integration | Requires coordination | Built in |
| Hospitalization impact | No documented advantage | 17.7% reduction (PMC) |
| Medical cost impact | No documented advantage | 3.7% reduction (PMC) |
| Specialty drug pricing | High control | Low control |
| Medicaid net pharmacy PMPM | $34.58 (Menges) | $38.47 (Menges) |
The carve-in case leans on care coordination and long-term medical trend. The carve-out case leans on contract hygiene and stopping PBM spread now. Neither is a clean win.
If your specialty drug spend is climbing and you can't explain why, the carve-out gives you the tools to find out. If your population carries high chronic disease burden, the carve-in integration argument gets harder to ignore. Your hospitalizations trending up makes it harder still.
The Decision You Should Be Making Deliberately
Most mid-market employers default to carve-in because they're fully insured or because the carrier made it easy. According to the KFF 2025 Employer Health Benefits Survey, 73% of covered workers at firms with 10 to 199 employees are still in fully insured plans. That makes carve-in the automatic default. The market is shifting, but the habit hasn't.
If you're self-funded and you've never negotiated a standalone PBM contract, you're leaving audit rights and rebate transparency on the table. If you're carve-out and your PBM isn't delivering direct rebate pass-through with auditable pricing, you have the structure but not the execution.
The $400 PMPY isn't a myth in either direction. It shows up as medical trend on one side and PBM spread on the other. The real question is whether your current setup lets you see either one clearly enough to act on it.